Position in OCUL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$103,561
-$58,368 QoQ
Shares Held
10,546
-44.8% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#198
of 257 holders
Holding Since
Sep 2022
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in OCUL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Graham Capital Management, L.P. holds $44,243,780 across 71 Biotechnology names. OCUL ranks #51 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
446,696 | $25,376,799 | |
| 2 | INCY |
Incyte Corp
|
15,632 | $1,772,043 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
16,717 | $1,325,490 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
22,114 | $862,667 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,256 | $679,123 | |
| 6 | ARVN |
Arvinas, Inc.
|
81,364 | $676,134 | |
| 7 | PCVX |
Vaxcyte, Inc.
|
11,107 | $645,649 | |
| 8 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
92,277 | $575,808 |
All Filings in OCUL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $103,561 | 10,546 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $161,929 | 19,118 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $200,358 | 16,504 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $436,399 | 37,331 | Shares | Sole | 2025-11-14 | |
| 2025-03-31 | $357,330 | 48,749 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $320,907 | 37,577 | Shares | Sole | 2025-02-14 | |
| 2023-09-30 | $299,439 | 95,363 | Shares | Sole | 2023-11-22 | |
| 2023-03-31 | $409,273 | 77,661 | Shares | Sole | 2023-05-15 | |
| 2022-09-30 | $789,002 | 190,121 | Shares | Sole | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||